4,469 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Focus Partners Wealth

Focus Partners Wealth bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,469 shares of the specialty pharmaceutical company's stock, valued at approximately $551,000.

Other hedge funds have also made changes to their positions in the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $25,000. Quadrant Capital Group LLC boosted its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the period. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 130 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In related news, CAO Patricia Carr sold 4,813 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Seamus Mulligan bought 1,621 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company's stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 28,236 shares of company stock valued at $3,956,190. Corporate insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on JAZZ shares. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Robert W. Baird cut their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded down $0.45 during trading on Thursday, hitting $107.82. 863,792 shares of the company were exchanged, compared to its average volume of 850,624. The firm has a 50 day moving average price of $113.50 and a 200 day moving average price of $121.91. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of 15.19, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the business posted $2.68 EPS. On average, equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.